Melbourne-based scientists have, for the first time, discovered how to "switch off" a molecule which is one of the top ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

A recent paper published by Johns Hopkins researchers in the Department of Computer Science details the development and use ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

Merck (MRK) stock in focus as anti-cancer agent Welireg is approved in the EU for kidney tumor conditions, VHL disease and ...

Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

There are currently 82,000 incident cases of RCC annually in the United States (account for 3–5% of cancers), with 15,000 deaths annually in the United States. The overall 5-year mortality risk is ~30 ...

Neoantigen-targeting PCVs are highly immunogenic in high-risk clear cell RCC and can target key driver mutations and induce antitumor immunity.

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell ...

A decade ago this past June, my sister died at the National Institutes of Health. I still have faith in them, and I hope that ...